Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 12-week Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Once Monthly Subcutaneous Erenumab 70 mg in Adult Chronic Migraine Patients

Next Previous
Search
Trial Profile

A 12-week Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Once Monthly Subcutaneous Erenumab 70 mg in Adult Chronic Migraine Patients

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Erenumab (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms DRAGON
  • Sponsors Novartis Pharmaceuticals

    • Most Recent Events

    • 10 Dec 2022 Results of sub analysis from Global DRAGON study (n=30) assessing the efficacy and safety of erenumab 70 mg in adult chronic migraine patients, presented at the 16th European headache federation Congress.
    • 26 Apr 2022 Primary endpoint (Change from baseline in monthly migraine days during the last 4 weeks of the 12-week treatment period) has been met according to the results presented at the 74th Annual Meeting of the American Academy of Neurology 2022
    • 26 Apr 2022 Results assessing efficacy and safety of once-monthly subcutaneous erenumab 70 mg in adult patients with chronic migraine (CM) presented at the 74th Annual Meeting of the American Academy of Neurology 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top